RegeneronCo-Founder, Co-Chair of the Board, President and Chief Scientific OfficerGeorge D. YancopoulosPh.D.Representation：“RegeneronIs one of the first to bet its future onDNAOne of the biotechnology companies with strength, which has driven our drugsR&D, thereby providing some of the world's leading and most innovative drugs, including those for the prevention of blindness.，Treatment of allergic diseases such as asthma and atopic dermatitisAndA variety of cancers, and even the treatment of Ebola andCOVID-19The drug. We have extensive experience in large-scale data management,Partners are spread acrossAll over the world, coming from nearly300Participants in the tens of thousandsGoIdentificationDNASequencing linked to electronic health records, driving securely and reliablyFocusFuture Advances in Medicine. We believe we can help23andMeAchieve its mission, helping those who want to understand themselvesDNAAnd customers interested in how to improve personal health, while further promotingRegeneron"Using large-scale genetic studies to improve the treatment and prevention of diseases."

Regeneron Genetics Center®Senior Vice President and HeadAris BarasPh.D.Indicates:“23andMeIt is consumption.LevelA pioneer in the field of genetics and research, we are delighted to have the opportunity to supportThisImportant Mission,Promote RelatedPlatform and Business. As a global leader in the field of human genetics,RegeneronHeredityThe center is dedicated to protecting the genetic data of customers around the world and using this data, with their consent, to advance science and society.。We are23andMeCustomer Guarantee,WillProtect with high standards of data privacy, security, and ethical oversight23andMeDataset, and will fully leverage its potential to improve human health。Self2013Since the year,RegeneronGeneticsCenterIn the researchRecently300The genetic information of ten thousand people has been sequenced, utilizing theseGoIdentified data,Achieved quickly and on a large scaleMeaningful findings. WeApproval23andMeThe founding vision, which is the power of genetics and data, as well as the health benefits of understanding the human genome for individuals and society. We believe,RegeneronVery suitable to become23andMeFuture Responsible and EffectiveManager.”

23andMeInterim CEOJoe SelsavageRepresentation:"We are pleased to have reached an agreement with a science-oriented partner, which will help ensure the advancement of our mission. InRegeneron"With the support and extensive experience in gene sequencing, testing, and discovery, we look forward to continuing to help people access and understand the human genome for the benefit of our customers and patients."

23andMeChairman and Member of the Special Committee of the BoardMark JensenSaid: "We are pleased to have reached a deal that maximizes the value of the enterprise.。RegeneronTo the acquired23andMeAll employees in the business department have been provided with employment opportunities.ThisMake23andMe's mission continues,That is, by better understanding the human genome, help people access, understand, and gain health benefits.At the same time，Maintained the key to customer privacy, choice, and consent regarding their genetic data.Protection.”